ALK-Abelló A/S
The answer first
Does ALK-Abelló beat the market?
No, ALK-Abelló has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 60% of Nordic stocks
- Quality95
- Value9
- Trend66
No. 49 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash ALK-Abelló keeps must grow about 11% a year for 10 years.
Max for seven days
Follow ALK-Abelló with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about ALK-Abelló
Your first answer is free, no account needed.
Do you own ALK-Abelló, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with ALK-Abelló and a few more. Free, no card.
Super Stock+44.6%In short
- ALK-Abelló has risen 4.5% over the past year, including dividends.
- Overall, ALK-Abelló ranks better than 60% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 55.9%. The price is 10.1% below its peak now.
What do analysts think of ALK-Abelló?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 60% of Nordic stocks.
No. 49 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 18 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.07
- Asset turnoverSales divided by everything the company owns0.70
- Return on equityProfit divided by equity+19.5%
- Cash conversionOperating cash flow divided by profit1.59
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 140 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity7.5
- P/SPrice divided by sales7.6
- P/EPrice divided by earnings38.2
- P/CFPrice divided by operating cash flow24.0
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 58 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+12.5%
- 6 months−7.6%
- 9 months+12.3%
- 12 months+4.5%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own ALK-Abelló
24 funds we follow own ALK-Abelló. The share is how much of the fund the stock makes up.
- Norway3
- Sweden17
- Denmark4
- 1 ETF
- Lannebo Hälsa och Ny Teknik ASweden · Lannebo4.4%
- Lannebo Norden BSweden · Lannebo2.3%
- Lannebo Norden Hållbar SEKSweden · Lannebo2.3%
- Handelsbanken Nordiska Småbol (A1 NOK)Sweden · Handelsbanken1.7%
- BIX Danske Aktier Indeks ADenmark · BIX1.5%
- BIX Danske Aktier Indeks Akk ADenmark · BIX1.5%
- Danske Invest Danmark IndeksDenmark · Danske Invest1.5%
- Handelsbanken Nordenfond (A1 NOK)Sweden · Handelsbanken1.4%
Show all 24
- Simplicity NordenSweden · Simplicity1.3%
- Sydinv Indeks Danmark A DKKDenmark · Sydinvest0.9%
- Lannebo SmåbolagSweden · Lannebo0.8%
- SEB EuropafondSweden · SEB0.8%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.5%
- Indecap Guide Sverige Offensiv CSweden · Indecap0.4%
- Levler MSCI Nordic by Xtrackers UCITS ETFSweden · Levler · ETF0.3%
- Alfred Berg Nordic Index R (SEK)Norway · Alfred Berg0.2%
- DNB Norden Indeks ANorway · DNB0.2%
- KLP AksjeNorden IndeksNorway · KLP0.2%
- Handelsbanken Gl Småbolag I Crit A9 EURSweden · Handelsbanken0.1%
- Handelsbanken Gl Småbolag Ind Cri A1 NOKSweden · Handelsbanken0.1%
- SEB Active 55 ASweden · SEB0.0%
- SEB Active 80 ASweden · SEB0.0%
- SEB Active 20 ASweden · SEB0.0%
- SEB Active 30 ASweden · SEB0.0%
From the funds' latest known holdings.
About ALK-Abelló
ALK-Abelló A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 2,600 employees.
ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies.


See the full analysis of ALK-Abelló.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card